| Name | Fingolimod |
| Description | Fingolimod (FTY-720A) is an antagonist of sphingosine 1-phosphate (S1P) (IC50 of 0.033 nM in K562 and NK cells). |
| Cell Research | Sciatic nerve crush was performed in wildtype C57BL/6, in immunodeficient Rag1 (-/-) and Foxn1 (-/-) mice.?Analyses were based on walking track analysis and electrophysiology, histology, and cAMP formation.?Quantification of different LPA species was performed by liquid chromatography coupled to tandem mass spectrometry.?Furthermore, functional consequences of autotaxin inhibition by the specific inhibitor PF-8380 and the impact of fingolimod on early cytokine release in the injured sciatic nerve were investigated[1]. |
| In vitro | Fingolimod has been reported to reduce LPA synthesis via inhibition of the lysophospholipase autotaxin.?Fingolimod treatment correlates with a significant elevation of axonal cAMP, a crucial factor for axonal outgrowth.?Additionally, Fingolimod significantly reduces LPA levels in the injured nerve.?PF-8380 treatment correlates with improved myelin thickness[1] |
| Storage | keep away from direct sunlight,store at low temperature,store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice./Shipping at ambient temperature. |
| Solubility Information | Methanol : 30 mg/mL (97.57 mM), Sonication is recommended.
Ethanol : 7.69 mg/mL (25.01 mM), Sonication is recommended.
DMSO : 1 mg/mL (3.25 mM), Sonication is recommended.
|
| Keywords | S1PReceptor | S1P Receptor | S1P | PAK | p21 activated kinases | Lysophospholipid Receptor | LPLReceptor | LPL Receptor | LPL | Inhibitor | inhibit | FTY720 | FTY 720 | Fingolimod |
| Inhibitors Related | Fingolimod hydrochloride | LX-2931 | Tyloxapol | Sphingosine-1-phosphate | CYM50374 | ASP-4058 | Ki16198 | Siponimod | 5-Aminosalicylic Acid | MP-A08 | S1PR1 modulator 1 | Ozanimod |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Alkaloid Natural Product Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Kinase Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |
United States
